Functional differences between NPFF1 and NPFF2 receptor coupling: High intrinsic activities of RFamide-related peptides on stimulation of [35S]GTPγS binding

Neuropharmacology

Volumn 52, Issue 2, 2007, Pages 376-386

  Gouarderes C ^a   Mazarguil, H ^a   Mollereau, C ^a   Chartrel, N ^b   Leprince, J ^b   Vaudry, H ^b   Zajac, J M ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b IFRMP 23   (France)

Author keywords

35S GTP S; G protein; NPFF; Receptor; RFamide

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE FF; NEUROPEPTIDE FF 1 RECEPTOR; NEUROPEPTIDE FF 2 RECEPTOR; PROLACTIN RELEASING FACTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ISOTOPE; NEUROPEPTIDE; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE RECEPTOR; RFAMIDE PEPTIDE; SAPONIN;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; ANIMAL; CELL MEMBRANE; CRICETULUS; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; HAMSTER; HUMAN; METABOLISM; PROTEIN BINDING; SCINTISCANNING;

ANIMALS; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GTP-BINDING PROTEIN ALPHA SUBUNITS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; ISOTOPES; NEUROPEPTIDES; PROTEIN BINDING; RECEPTORS, NEUROPEPTIDE; SAPONINS;

EID: 33846333066     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.07.034     Document Type: Article

References (34)

1. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., Smith K.E., Tamm J.A., Boteju L.W., Lakhlani P.P., Raddatz R., Yao W.J., Ogozalek K.L., Boyle N., Kouranova E.V., Quan Y., Vaysse P.J., Wetzel J.M., Branchek T.A., Gerald C., and Borowsky B. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 275 (2000) 39324-39331
2. Bonnard E., Burlet-Schiltz O., Frances B., Mazarguil H., Monsarrat B., Zajac J.M., and Roussin A. Identification of neuropeptide FF-related peptides in rodent spinal cord. Peptides 22 (2001) 1085-1092
3. Breivogel C.S., Selley D.E., and Childers S.R. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem. 273 (1998) 16865-16873
4. Brink C.B., Wade S.M., and Neubig R.R. Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s). J. Pharmacol. Exp. Ther. 294 (2000) 539-547
5. Burford N.T., and Nahorski S.R. Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gs alpha and is not a consequence of phosphoinositidase C activation. Biochem. J. 315 Pt 3 (1996) 883-888
6. Chartrel N., Bruzzone F., Dujardin C., Leprince J., Tollemer H., Anouar Y., Vallarino M., Costentin J., and Vaudry H. Identification of 26RFa from Frog Brain: A novel hypothalamic neuropeptide with orexigenic activity in mammals. Ann. N.Y. Acad. Sci. 1040 (2005) 80-83
7. Chartrel N., Dujardin C., Anouar Y., Leprince J., Decker A., Clerens S., Do-Rego J.C., Vandesande F., Llorens-Cortes C., Costentin J., Beauvillain J.C., and Vaudry H. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15247-15252
8. Ehlert F.J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28 (1985) 410-421
9. Elshourbagy N.A., Ames R.S., Fitzgerald L.R., Foley J.J., Chambers J.K., Szekeres P.G., Evans N.A., Schmidt D.B., Buckley P.T., Dytko G.M., Murdock P.R., Milligan G., Groarke D.A., Tan K.B., Shabon U., Nuthulaganti P., Wang D.Y., Wilson S., Bergsma D.J., and Sarau H.M. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J. Biol. Chem. 275 (2000) 25965-25971
10. Engstrom M., Brandt A., Wurster S., Savola J.M., and Panula P. Prolactin releasing peptide has high affinity and efficacy at neuropeptide FF2 receptors. J. Pharmacol. Exp. Ther. 305 (2003) 825-832
11. Gettys T.W., Sheriff-Carter K., Moomaw J., Taylor I.L., and Raymond J.R. Characterization and use of crude alpha-subunit preparations for quantitative immunoblotting of G proteins. Anal. Biochem. 220 (1994) 82-91
12. Gicquel S., Mazarguil H., Desprat C., Allard M., Devillers J.-P., Simonnet G., and Zajac J.-M. Structure-activity study of Neuropeptide FF: contribution of N-terminal regions to affinity and activity. J. Med. Chem. 37 (1994) 3477-3481
13. Gilchrist A., Mazzoni M.R., Dineen B., Dice A., Linden J., Proctor W.R., Lupica C.R., Dunwiddie T.V., and Hamm H.E. Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J. Biol. Chem. 273 (1998) 14912-14919
14. Gouarderes C., Quelven I., Mollereau C., Mazarguil H., Rice S.Q., and Zajac J.M. Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience 115 (2002) 349-361
15. Gu W., Geddes B.J., Zhang C., Foley K.P., and Stricker-Krongrad A. The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice. J. Mol. Neurosci. 22 (2004) 93-103
16. Harrison C., and Traynor J.R. The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci. 74 (2003) 489-508
17. Hinuma S., Habata Y., Fujii R., Kawamata Y., Hosoya M., Fukusumi S., Kitada C., Masuo Y., Asano T., Matsumoto H., Sekiguchi M., Kurokawa T., Nishimura O., Onda H., and Fujino M. A prolactin-releasing peptide in the brain [comment] [erratum appears in Nature 1998 Jul 16;394(6690):302]. Nature 393 (1998) 272-276
18. Hinuma S., Shintani Y., Fukusumi S., Iijima N., Matsumoto Y., Hosoya M., Fujii R., Watanabe T., Kikuchi K., Terao Y., Yano T., Yamamoto T., Kawamata Y., Habata Y., Asada M., Kitada C., Kurokawa T., Onda H., Nishimura O., Tanaka M., Ibata Y., and Fujino M. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat. Cell Biol. 2 (2000) 703-708
19. Jhamandas K., Milne B., Sutak M., Gouarderes C., Zajac J.M., and Yang H.Y. Facilitation of spinal morphine analgesia in normal and morphine tolerant animals by neuropeptide SF and related peptides. Peptides 27 (2006) 953-963
20. Jiang Y., Luo L., Gustafson E.L., Yadav D., Laverty M., Murgolo N., Vassileva G., Zeng M., Laz T.M., Behan J., Qiu P., Wang L., Wang S., Bayne M., Greene J., Monsma Jr. F., and Zhang F.L. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J. Biol. Chem. 278 (2003) 27652-27657
21. Kersanté F., Mollereau C., Zajac J.-M., and Roumy M. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 27 (2006) 980-989
22. Kotani M., Mollereau C., Detheux M., Le Poul E., Brezillon S., Vakili J., Mazarguil H., Vassart G., Zajac J.M., and Parmentier M. Functional characterization of a human receptor for neuropeptide FF and related peptides. Br. J. Pharmacol. 133 (2001) 138-144
23. Law S.F., Yasuda K., Bell G.I., and Reisine T. Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. J. Biol. Chem. 268 (1993) 10721-10727
24. Mazarguil H., Gouarderes C., Tafani J.A., Marcus D., Kotani M., Mollereau C., Roumy M., and Zajac J.M. Structure-activity relationships of neuropeptide FF: role of C-terminal regions. Peptides 22 (2001) 1471-1478
25. Mazzoni M.R., Taddei S., Giusti L., Rovero P., Galoppini C., D'Ursi A., Albrizio S., Triolo A., Novellino E., Greco G., Lucacchini A., and Hamm H.E. A Galpha(s) carboxyl-terminal peptide prevents G(s) activation by the A(2A) adenosine receptor. Mol. Pharmacol. 58 (2000) 226-236
26. Mollereau C., Mazarguil H., Zajac J.M., and Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 67 (2005) 965-975
27. Mollereau C., Mazarguil H., Marcus D., Quelven I., Kotani M., Lannoy V., Dumont Y., Quirion R., Detheux M., Parmentier M., and Zajac J.M. Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur. J. Pharmacol. 451 (2002) 245-256
28. Newman-Tancredi A., Cussac D., Marini L., and Millan M.J. Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol. Pharmacol. 62 (2002) 590-601
29. Perry S.J., Huang E.Y., Cronk D., Bagust J., Sharma R., Walker R.J., Wilson S., and Burke J.F. A human gene encoding morphine modulating peptides related to NPFF and FMRFamide. FEBS Lett. 409 (1997) 426-430
30. Roumy M., and Zajac J.M. Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 345 (1998) 1-11
31. Roumy M., Garnier M., and Zajac J.-M. Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurons. Neurosci. Lett. 348 (2003) 159-162
32. Samson W.K., and Taylor M.M. Prolactin releasing peptide (PrRP): An endogenous regulator of cell growth. Peptides 27 (2006) 1099-1103
33. Szekeres P.G., and Traynor J.R. Delta opioid modulation of the binding of guanosine-5′-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther. 283 (1997) 1276-1284
34. Thuau R., Guilhaudis L., Segalas-Milazzo I., Chartrel N., Oulyadi H., Boivin S., Fournier A., Leprince J., Davoust D., and Vaudry H. Structural studies on 26RFa, a novel human RFamide-related peptide with orexigenic activity. Peptides 26 (2005) 779-789